ArticlePharmacoEconomics2014
Can the real opportunity cost stand up: displaced services, the straw man outside the room.
Article in PharmacoEconomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation.PharmacoEconomics · 2019Trial
- Behavioral response and cost comparison of manual versus pharmacologic restraint protocols in healthy dogs.The Canadian veterinary journal = La revue veterinaire canadienne · 2016Trial
- Aligning opportunity cost and net benefit criteria: the health shadow price.Frontiers in public health · 2024Article
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
- The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.PharmacoEconomics · 2022Article
- [Flu vaccination and value-based health care: operational solutions to safeguard public health].Journal of preventive medicine and hygiene · 2022Article
- Multiple effects health economic evaluation of the Ahead of The Game Study for mental health promotion in sporting club communities.Health economics review · 2021Article
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations.Social science & medicine (1982) · 2019Article
- Cost-Effectiveness Thresholds: the Past, the Present and the Future.PharmacoEconomics · 2018Review
- Estimating the opportunity costs of bed-days.Health economics · 2018Article
- Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.Clinical drug investigation · 2016Article
- What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.PharmacoEconomics · 2016Article
- The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?PharmacoEconomics · 2016Article
- Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.PloS one · 2015Article
- NICE's cost-effectiveness range: should it be lowered?PharmacoEconomics · 2014Article
- Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?PharmacoEconomics · 2014Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In current literature, displaced services have been suggested to provide a basis for determining a threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed. We critically examine the conditions under which displaced services would represent an economically meaningful threshold value. We first show that if we assume that the least cost-effective services are displaced to finance a new technology, then the incremental cost-effectiveness ratio (ICER) of the displaced services (d) only coincides with that related to the opportunity cost of adopting that new technology, the ICER of the most cost-effective service in expansion (n), under highly restrictive conditions-namely, complete allocative efficiency in existing provision of health care interventions. More generally, reimbursement of new technology with a fixed budget comprises two actions; adoption and financing through displacement and the effect of reimbursement is the net effect of these two actions. In order for the reimbursement process to be a pathway to allocative efficiency within a fixed budget, the net effect of the strategy of reimbursement is compared with the most cost-effective alternative strategy for reimbursement: optimal reallocation, the health gain maximizing expansion of existing services financed by the health loss minimizing contraction. The shadow price of the health effects of a new technology, βc = (1/n + 1/d - 1/m)(-1), accounts for both imperfect displacement (the ICER of the displaced service, d < m, the ICER of the least cost-effective of the existing services in contraction) and the allocative inefficiency (n < m) characteristic of health systems.
Indexed as
Identifiers
24515251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.